Subcutaneously implanted human HER2-positive tumor cells such as the Trastuzumab-sensitive BT474 cell line in PBMC-engrafted immunodeficient mice may represent an alternative in vivo model that excludes efficient access of untargeted CpG ODN to the tumor tissue. This evidence concerns the gene ERBB2 and neoplasm.